title: [Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action in alloxan diabetes].
abstract: Relationship between the antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives (emoxipine, reamberin and mexidol) and their effect on conditional learning, glycemia, and lipidemia was studied in rats with alloxan-induced diabetes. In parallel, the analogous relationship was investigated for alpha-lipoic acid that is regarded as a "gold standard" in treatment of diabetic neuropathy. It was established that single administration of emoxipine and mexidol in mice in doses equivalent to therapeutic-range doses in humans produces antihypoxic effect manifested by increased resistance to acute hypoxic hypoxia in test animals. Alpha-lipoic acid is inferior to emoxipin and mexidol in the degree of antihypoxic action. Reamberin does not exhibit this effect. The introduction of emoxipin, reamberin, mexidol, and alpha-lipoic acid in rats with alloxan diabetes during 7 or 14 days in doses equivalent to therapeutic-range doses in humans corrects conditional learning disorders in direct relationship with the antihypoxic activity of these drugs. The development of the nootropic effect of emoxipin, mexidol, and alpha-lipoic acid is related to a decrease in hyperglycemia and hyperlipidemia in rats with alloxan diabetes. The nootropic action of reamberin is accompanied by a transient hypoglycemizing effect and aggravation of dyslipidemic disorders. The antihypoxic activity of investigated drugs determines the direction and expression of their lipidemic effect, but is not correlated with the hypoglycemizing action these drugs on test animals with alloxan diabetes.
authors.forename: I A
authors.initials: IA
authors.lastname: Volchegorskiĭ
authors.forename: L M
authors.initials: LM
authors.lastname: Rassokhina
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Miroshnichenko
mesh_terms: D000496:Alloxan / Q000494:pharmacology; D000818:Animals; D003214:Conditioning, Classical / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003929:Diabetic Neuropathies / Q000378:metabolism / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006943:Hyperglycemia / Q000378:metabolism / Q000517:prevention & control; D006949:Hyperlipidemias / Q000378:metabolism / Q000517:prevention & control; D000860:Hypoxia / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D051379:Mice; D018697:Nootropic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D010847:Picolines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D013386:Succinates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D008063:Thioctic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D018697:Nootropic Agents; D010847:Picolines; D011725:Pyridines; C549374:Reamberin; D013386:Succinates; C070020:emoxypine succinate; C023500:3-hydroxypyridine; D008536:Meglumine; D000496:Alloxan; D008063:Thioctic Acid; C009820:6-methyl-2-ethyl-3-hydroxypyridine